Phaseline

Companies › Integrative Skin Science and Research

Integrative Skin Science and Research: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 4; Immunology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Sarecycline
Tetracycline antibiotic with preferential activity against Propionibacterium acnes
–Phase 4Acne VulgarisApr 2027
Roflumilast
Phosphodiesterase 4 inhibitor
PDE4A, PDE4D, PDE4B, PDE4CPhase 4ITCHAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07544251SarecyclinePhase 4Acne VulgarisImmunologyApr 2027
NCT07560618RoflumilastPhase 4ITCHImmunologyAug 2027

Targets

PDE4A (1) PDE4D (1) PDE4B (1) PDE4C (1)

Companies with the same targets

Amgen MediciNova Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA Ganzhou Hemay Pharmaceutical Merck & Co. (MSD) Arcutis Biotherapeutics Shionogi Tetra Discovery Partners

Companies built like this

Palisade Bio Ganzhou Hemay Pharmaceutical Pharvaris Netherlands AUG Therapeutics Lynk Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.